NVAX Jan 2025 15.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:50AM EDT. Market open.
| Previous close | 4.8800 |
| Open | 4.8800 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 15.00 |
| Expiry date | 2025-01-17 |
| Day's range | 4.8800 - 4.8800 |
| Contract range | N/A |
| Volume | |
| Open interest | 748 |
GlobeNewswireShah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value Still Remains to Be Unlocked at Novavax Still Believes Novavax Would Benefit from Stockholder Representative on Board RALEIGH, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Shah Capital Management, Inc. (together with its affiliates, “Shah Capital,” “we” or “our”) collectively beneficially owns ~7.9% of the outstanding common stock of Novavax, Inc. (NASDAQ: NVAX) (“Novavax” or the “Company”), making it
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
© 2024 Yahoo. All rights reserved.